Clinical trials: Chronic Kidney Disease in Type 2 Diabetes
Chronic Kidney Diseases, Albuminuria
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors
a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other…
- Conditions
- Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies
- Trial name
- PRIMETIME2 (NCT04916132)
- Testing
- Kidney Biopsy
- Where
- 13 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Herlev Hospital
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.
- Trial name
- NCT00509262
- Testing
- Sitagliptin, Glipizide
- Volunteers
- 426 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients
This is an observational study in which data from people with type 2 diabetes mellitus (T2DM) in Germany who use the medical app "myTherapy" are studied.
- Trial name
- SMART-Finder (NCT05552339)
- Testing
- Finerenone (Kerendia, BAY94-8862), Type 2 DM drugs
- Where
- Germany
- Volunteers
- 348 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (HbA1c) reduction at Week 26 in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD4 (NCT03242018)
- Testing
- Sotagliflozin
- Where
- 106 sites in United States, Argentina and 13 more
- Volunteers
- 277 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a…
- Trial name
- NCT06297603
- Testing
- Retatrutide
- Where
- 76 sites in United States, Argentina and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Renal Disorder Associated With Type II Diabetes Mellitus
Type 2 Diabetes Mellitus and Chronic Kidney Disease
To investigate the effect of co existance of diabetes mellitus and chronic kidney disease on basic coagulation profile in comparison with diabetic patients with normal kidney function and non diabetic patients with chronic kidney…
- Trial name
- NCT04971252
- Testing
- Hematologic tests for patients with diabetes mellitus and chronic kidney disease
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease, Type 2 Diabetes
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Obesity
- Trial name
- NCT06131372
- Testing
- Cagrilintide, Semaglutide
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 626 people
- Sponsor
- Novo Nordisk A/S
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study is to evaluate the pharmacokinetics and pharmacodynamics of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.
- Trial name
- NCT01549769
- Testing
- Bardoxolone Methyl
- Volunteers
- 24 people
- Sponsor
- Biogen
Eye Diseases, Renal Impairment
Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease
This study evaluate the frequency and type of eye problem among Type 2 Diabetics with renal impairment and effect of renal impairment and haemodialysis on diabetic retinopathy
- Conditions
- Eye Diseases, Renal Impairment, Type2 Diabetes
- Trial name
- NCT03330054
- Testing
- fundoscope
- Volunteers
- 100 people
- Sponsor
- Mohammed Ramadan Abdallah
Chronic Kidney Disease stage3 and 4, Type 2 Diabetes Mellitus
Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)
One of the purposes of the management of the patient with chronic kidney disease (CKD)is to slow the decline of renal function. The mechanisms by which the renal function declines involve inflammatory and fibrotic responses due…
- Trial name
- PENFOSIDINE (NCT03664414)
- Testing
- pentoxifylline
- Where
- Mexico
- Volunteers
- 196 people
- Sponsor
- Maria Eugenia Galván Plata
Diabetic Kidney Disease, Diabetes Type 2
Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes
The Investigators will generate a repository of human biosamples across therapeutic areas that will be used to identify disease-associated biomarkers and potential targets with immune and multi-omics profiling.
- Conditions
- Diabetic Kidney Disease, Diabetes Type 2, Chronic Kidney Diseases, Healthy
- Trial name
- SAN-08961 (NCT05631119)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sanguine Biosciences
Dialysis, Chronic Kidney Disease
Next Generation Advanced Insulin Delivery System in Adults With Diabetes and Advanced Renal Disease
The goal of this this randomized, clinical trial is to test an automated insulin delivery system (AID) in people with type 1 or type 2 diabetes who are on hemodialysis, peritoneal dialysis, or have advanced chronic kidney disease…
- Conditions
- Dialysis, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT06330194
- Testing
- 2nd Generation Automated Insulin Delivery (AID) system
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Steno Diabetes Center Copenhagen
Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4
Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2
This research project aims to test if sulforaphane, administered as broccoli sprout extract (BSE) can ameliorate glucose control in adult patients with chronic kidney disease (CKD) and DM 2 with GFR > 15 < 45 ml/min/1.73 m2.
- Conditions
- Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4, Diabetes Mellitus, Type 2
- Trial name
- INITIATE (NCT04858854)
- Testing
- Sulforaphane, administered as Broccoli sprout extract
- Where
- 12 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Karolinska Institutet
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
This is a prospective observational study in which data from people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who will be receiving finerenone are collected and analyzed.
- Trial name
- FINEXPLORER (NCT07554469)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Bayer
Cardiovascular Diseases (CVD), Type 2 Diabetes
Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction
This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and…
- Conditions
- Cardiovascular Diseases (CVD), Type 2 Diabetes, Chronic Respiratory Diseases, Obesity (Disorder)
- Trial name
- NCT06953180
- Testing
- Genetic: DNA analysis
- Where
- Kazakhstan
- Volunteers
- 6,720 people, healthy volunteers welcome
- Sponsor
- Asfendiyarov Kazakh National Medical University
Type 2 Diabetes Mellitus, End-stage Renal Disease
Liraglutide Treatment to Patients With Severe Renal Insufficiency
Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is new and fundamentally different from the classical treatments with oral antidiabetic agents and insulin.
- Trial name
- NCT01394341
- Testing
- Liraglutide
- Where
- 3 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Bo Feldt-Rasmussen
Type 2 Diabetes With Renal Manifestations
Predictors of Chronic Kidney Disease Among Type 2 Diabetic Patients in Assiut University Hospitals
Predictors of Chronic Kidney Disease among Type 2 Diabetic Patients in Assiut University Hospitals.
- Trial name
- Ckd&dm (NCT05847400)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Assiut University
Heart Failure, Coronary Artery Disease
COVID-19 Testing in Underserved and Vulnerable Populations
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to…
- Conditions
- Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases
- Trial name
- NCT05315908
- Testing
- Community outreach method
- Where
- United States
- Volunteers
- 9,120 people
- Sponsor
- Jesse Nodora
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company